date:Aug 21, 2014
ugar, aiding them in reaching their product cost targets, and allowing for scalability, which is said to be difficult via the leaf.
This breakthrough will allow consumers all over the world to enjoy products using Reb M at a commercially viable price, said Neil Goldsmith, Evolva CEO. This patent application forms part of our ever-expanding IP portfolio on steviol glycosides, which we are confident is the most extensive, and the most commercially significant in this space.
We are pleased about